应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
APLS Apellis Pharmaceuticals Inc.
交易中 07-09 10:38:14 EDT
18.43
+0.54
+2.99%
最高
18.65
最低
18.07
成交量
37.25万
今开
18.07
昨收
17.89
日振幅
3.24%
总市值
23.16亿
流通市值
14.27亿
总股本
1.26亿
成交额
687.01万
换手率
0.48%
流通股本
7,747万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
【大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级】智通财经A
智通财经 · 07-07 03:58
【大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级】智通财经A
大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级
智通财经 · 07-07 03:58
大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级
Apellis Pharmaceuticals, Inc.盘中异动 大幅拉升5.03%报18.18美元
市场透视 · 07-01
Apellis Pharmaceuticals, Inc.盘中异动 大幅拉升5.03%报18.18美元
Apellis Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.00%
市场透视 · 06-27
Apellis Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.00%
Apellis Pharmaceuticals, Inc.盘中异动 急速拉升5.05%报18.51美元
市场透视 · 06-24
Apellis Pharmaceuticals, Inc.盘中异动 急速拉升5.05%报18.51美元
花旗:维持Apellis Pharmaceuticals(APLS.US)评级,由买入调整至买入评级, 目标价由49.00美元调整至41.00美元。
金融界 · 05-22
花旗:维持Apellis Pharmaceuticals(APLS.US)评级,由买入调整至买入评级, 目标价由49.00美元调整至41.00美元。
Apellis Pharmaceuticals, Inc.盘中异动 下午盘急速上涨5.04%报18.56美元
市场透视 · 05-20
Apellis Pharmaceuticals, Inc.盘中异动 下午盘急速上涨5.04%报18.56美元
Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.01%
市场透视 · 05-16
Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.01%
Apellis Pharmaceuticals, Inc.2025财年第一财季实现净利润-92.23百万美元,同比减少38.86%
市场透视 · 05-15
Apellis Pharmaceuticals, Inc.2025财年第一财季实现净利润-92.23百万美元,同比减少38.86%
异动解读 | Apellis Pharmaceuticals盘中大跌5.03%,瑞穗下调目标价
异动解读 · 05-14
异动解读 | Apellis Pharmaceuticals盘中大跌5.03%,瑞穗下调目标价
异动解读 | 瑞穗下调目标价,Apellis Pharmaceuticals盘中大跌5.03%
异动解读 · 05-14
异动解读 | 瑞穗下调目标价,Apellis Pharmaceuticals盘中大跌5.03%
Apellis Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.03%报16.41美元
市场透视 · 05-14
Apellis Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.03%报16.41美元
瑞穗银行:维持Apellis Pharmaceuticals(APLS.US)评级,由中性调整至中性评级, 目标价由30.00美元调整至20.00美元。
金融界 · 05-14
瑞穗银行:维持Apellis Pharmaceuticals(APLS.US)评级,由中性调整至中性评级, 目标价由30.00美元调整至20.00美元。
B of A Securities:下调Apellis Pharmaceuticals(APLS.US)评级,由买入调整至中性评级, 目标价由41.00美元调整至23.00美元。
金融界 · 05-09
B of A Securities:下调Apellis Pharmaceuticals(APLS.US)评级,由买入调整至中性评级, 目标价由41.00美元调整至23.00美元。
加拿大皇家银行:维持Apellis Pharmaceuticals(APLS.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由21.00美元调整至18.00美元。
金融界 · 05-08
加拿大皇家银行:维持Apellis Pharmaceuticals(APLS.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由21.00美元调整至18.00美元。
Scotiabank:维持Apellis Pharmaceuticals(APLS.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由28.00美元调整至20.00美元。
金融界 · 05-08
Scotiabank:维持Apellis Pharmaceuticals(APLS.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由28.00美元调整至20.00美元。
富国银行:维持Apellis Pharmaceuticals(APLS.US)评级,由持股观望调整至持股观望评级, 目标价由30.00美元调整至26.00美元。
金融界 · 05-08
富国银行:维持Apellis Pharmaceuticals(APLS.US)评级,由持股观望调整至持股观望评级, 目标价由30.00美元调整至26.00美元。
Baird:维持Apellis Pharmaceuticals评级,由优于大市调整至优于大市评级, 目标价由55.00美元调整至47.00美元。
金融界 · 05-08
Baird:维持Apellis Pharmaceuticals评级,由优于大市调整至优于大市评级, 目标价由55.00美元调整至47.00美元。
Apellis Pharmaceuticals, Inc.盘中异动 快速下跌10.25%
市场透视 · 05-07
Apellis Pharmaceuticals, Inc.盘中异动 快速下跌10.25%
Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.00%
市场透视 · 04-30
Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.00%
加载更多
公司概况
公司名称:
Apellis Pharmaceuticals Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Apellis Pharmaceuticals, Inc.于2009年9月25日根据德拉华州法律成立。该公司是一家商业阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物,通过在补体级联中的中心蛋白C3水平上抑制补体系统(作为免疫系统的一个组成部分)来治疗具有高度未满足需求的疾病。2023年2月,美国食品药品监督管理局(FDA)批准了SYFOVRE,这是首个获批治疗继发于年龄相关性黄斑变性(GA)的地理萎缩的药物。
发行价格:
--
{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":18.425,"timestamp":1752071893577,"preClose":17.89,"halted":0,"volume":372501,"delay":0,"floatShares":77466271,"shares":125682260,"eps":-1.796208,"marketStatus":"交易中","change":0.535,"latestTime":"07-09 10:38:14 EDT","open":18.07,"high":18.65,"low":18.07,"amount":6870127.205745,"amplitude":0.03242,"askPrice":18.44,"askSize":200,"bidPrice":18.41,"bidSize":306,"shortable":3,"etf":0,"ttmEps":-1.796208,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1752091200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":17.89,"preHourTrading":{"tag":"盘前","latestPrice":18.07,"preClose":17.89,"latestTime":"09:29 EDT","volume":435,"amount":7747.35957,"timestamp":1752067787071},"postHourTrading":{"tag":"盘后","latestPrice":17.87,"preClose":17.89,"latestTime":"19:26 EDT","volume":1277256,"amount":22850095.37,"timestamp":1752017182565},"volumeRatio":1.093671,"optionData":{"bulkOrders":[{"symbol":"APLS","call":true,"expireDate":1760673600000,"strike":"20.0","timestamp":1752070813944,"price":2.4,"volume":2500,"amount":600000,"type":"+"}]},"impliedVol":0.877,"impliedVolPercentile":0.96},"requestUrl":"/m/hq/s/APLS","defaultTab":"news","newsList":[{"id":"2549430900","title":"【大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级】智通财经A","url":"https://stock-news.laohu8.com/highlight/detail?id=2549430900","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549430900?lang=zh_cn&edition=full","pubTime":"2025-07-07 11:58","pubTimestamp":1751860703,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1162221912.USD","LU0234570918.USD","IE00BKVL7J92.USD","LU1074936037.SGD","LU1989772923.USD","BK4504","LU2028103732.USD","LU0795875086.SGD","LU0971096721.USD","BK4588","LU2271345857.HKD","LU0225283273.USD","LU1548497426.USD","APLS","BK4505","LU0106261372.USD","IE00BZ1G4Q59.USD","LU0006306889.USD","LU1668664300.SGD","LU1720051017.SGD","BK4516","BK4581","LU0106831901.USD","LU1093756325.SGD","LU2089283258.USD","LU2111349929.HKD","LU0795875169.SGD","LU1732799900.SGD","LU1363072403.SGD","LU0098860793.USD","LU1732800096.USD","BK4585","LU1989772840.SGD","LU2357305700.SGD","BK4127","BK4534","LU2023251221.USD","LU2089284900.SGD","LU0158827948.USD","LU0267386448.USD","LU0314104364.USD","LU0158827781.USD","BK4139","LU1093756168.USD","LU1720051108.HKD","LU2133065610.SGD","LU2347655156.SGD","LU0912757837.SGD","LU0320765646.SGD"],"gpt_icon":0},{"id":"2549090003","title":"大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2549090003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549090003?lang=zh_cn&edition=full","pubTime":"2025-07-07 11:58","pubTimestamp":1751860703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,摩根士丹利分析师Judah Frommer发表研报,将Apellis Pharmaceuticals目标价从25美元上调至26美元,同时维持“持有”评级。Frommer表示,这一评级是基于该公司市场地位及近期财务战略所作出的判断。这一举措不仅为Apellis带来即时财务收益,甚至有望缓解投资者对其盈利能力的担忧。尽管存在这些积极因素,Frommer仍对Apellis的未来发展保持审慎态度。据了解,作为一家处于商业化阶段的生物制药企业,Apellis致力于发现、开发和商业化治疗未满足医疗需求的创新疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["APLS"],"gpt_icon":0},{"id":"2548999883","title":"Apellis Pharmaceuticals, Inc.盘中异动 大幅拉升5.03%报18.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548999883","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548999883?lang=zh_cn&edition=full","pubTime":"2025-07-01 23:35","pubTimestamp":1751384154,"startTime":"0","endTime":"0","summary":"北京时间2025年07月01日23时35分,Apellis Pharmaceuticals, Inc.股票出现波动,股价快速上涨5.03%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.87%。Apellis Pharmaceuticals, Inc.公司简介:Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物, 通过抑制补体系统来治疗具有高度未满足需求的疾病,在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012335549796128f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507012335549796128f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU1093756325.SGD","BK4505","LU1093756168.USD","BK4139","BK4585","APLS"],"gpt_icon":0},{"id":"2546872546","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546872546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546872546?lang=zh_cn&edition=full","pubTime":"2025-06-28 02:41","pubTimestamp":1751049671,"startTime":"0","endTime":"0","summary":"北京时间2025年06月28日02时41分,Apellis Pharmaceuticals, Inc.股票出现波动,股价快速跳水5.00%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.67%。Apellis Pharmaceuticals, Inc.公司简介:Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物, 通过抑制补体系统来治疗具有高度未满足需求的疾病,在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628024111a4c1bb7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250628024111a4c1bb7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU1093756168.USD","BK4585","APLS","LU1093756325.SGD","BK4588","BK4505"],"gpt_icon":0},{"id":"2545231534","title":"Apellis Pharmaceuticals, Inc.盘中异动 急速拉升5.05%报18.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545231534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545231534?lang=zh_cn&edition=full","pubTime":"2025-06-24 23:24","pubTimestamp":1750778665,"startTime":"0","endTime":"0","summary":"北京时间2025年06月24日23时24分,Apellis Pharmaceuticals, Inc.股票出现波动,股价大幅上涨5.05%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.76%。Apellis Pharmaceuticals, Inc.公司简介:Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物, 通过抑制补体系统来治疗具有高度未满足需求的疾病,在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624232425a4bbbc83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624232425a4bbbc83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","APLS","LU1093756325.SGD","BK4505","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2537294926","title":"花旗:维持Apellis Pharmaceuticals(APLS.US)评级,由买入调整至买入评级, 目标价由49.00美元调整至41.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2537294926","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537294926?lang=zh_cn&edition=full","pubTime":"2025-05-23 01:24","pubTimestamp":1747934658,"startTime":"0","endTime":"0","summary":"花旗:维持Apellis Pharmaceuticals(APLS.US)评级,由买入调整至买入评级, 目标价由49.00美元调整至41.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/23012450601766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["APLS"],"gpt_icon":0},{"id":"2537180647","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘急速上涨5.04%报18.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537180647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537180647?lang=zh_cn&edition=full","pubTime":"2025-05-21 02:03","pubTimestamp":1747764194,"startTime":"0","endTime":"0","summary":"北京时间2025年05月21日02时03分,Apellis Pharmaceuticals, Inc.股票出现异动,股价急速拉升5.04%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.84%。Apellis Pharmaceuticals, Inc.公司简介:Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物, 通过抑制补体系统来治疗具有高度未满足需求的疾病,在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521020315a6e6597c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250521020315a6e6597c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","APLS","NRXS","BK4139","BK4082","BK4505","LU1093756325.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2535882314","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535882314","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535882314?lang=zh_cn&edition=full","pubTime":"2025-05-16 22:46","pubTimestamp":1747406762,"startTime":"0","endTime":"0","summary":"北京时间2025年05月16日22时46分,Apellis Pharmaceuticals, Inc.股票出现异动,股价大幅拉升5.01%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.41%。Apellis Pharmaceuticals, Inc.公司简介:Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物, 通过抑制补体系统来治疗具有高度未满足需求的疾病,在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516224602aa2c9171&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516224602aa2c9171&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU1093756168.USD","BK4588","BK4585","BK4505","APLS","LU1093756325.SGD"],"gpt_icon":0},{"id":"2535873852","title":"Apellis Pharmaceuticals, Inc.2025财年第一财季实现净利润-92.23百万美元,同比减少38.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535873852","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535873852?lang=zh_cn&edition=full","pubTime":"2025-05-16 00:00","pubTimestamp":1747324847,"startTime":"0","endTime":"0","summary":"5月16日,Apellis Pharmaceuticals, Inc.公布财报,公告显示公司2025财年第一财季净利润为-92.23百万美元,同比减少38.86%;其中营业收入为1.67亿美元,同比减少2.91%,每股基本收益为-0.74美元。从资产负债表来看,Apellis Pharmaceuticals, Inc.总负债6.43亿美元,其中短期债务6.94百万美元,资产负债比为1.26,流动比率为4.09。机构评级:截至2025年5月16日,当前有21家机构对Apellis Pharmaceuticals, Inc.目标价做出预测,其中目标均价为36.62美元,其中最低目标价为18.00美元,最高目标价为60.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516000202a6e08e84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516000202a6e08e84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS"],"gpt_icon":0},{"id":"1121713116","title":"异动解读 | Apellis Pharmaceuticals盘中大跌5.03%,瑞穗下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1121713116","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121713116?lang=zh_cn&edition=full","pubTime":"2025-05-15 02:15","pubTimestamp":1747246526,"startTime":"0","endTime":"0","summary":"周三盘中,Apellis Pharmaceuticals(股票代码:APLS)股价大跌5.03%,引发市场关注。\n\n此次下跌主要源于瑞穗证券分析师对该公司股票的最新评估。根据消息,瑞穗将Apellis Pharmaceuticals的目标价从30美元大幅下调至20美元,降幅达33.33%。尽管瑞穗维持了对该股的\"中性\"评级,但目标价的显著下调无疑打击了投资者信心。\n\n分析人士指出,瑞穗此次下调目标价可能反映了对Apellis Pharmaceuticals未来业务发展或财务表现的担忧。然而,具体原因尚未公开。投资者正密切关注公司后续可能发布的相关声明或财报,以进一步评估其投资价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"gpt_icon":0},{"id":"1129733605","title":"异动解读 | 瑞穗下调目标价,Apellis Pharmaceuticals盘中大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129733605","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129733605?lang=zh_cn&edition=full","pubTime":"2025-05-15 02:14","pubTimestamp":1747246482,"startTime":"0","endTime":"0","summary":"5月14日周三,Apellis Pharmaceuticals股价盘中大跌5.03%,引发市场关注。导致股价下跌的主要原因是,瑞穗银行分析师大幅下调了Apellis Pharmaceuticals的目标价。根据最新研报,瑞穗将该公司的目标价从30美元下调至20美元,降幅达33.33%。分析师的目标价调整往往会对投资者情绪产生显著影响。需要注意的是,目前观察到的是盘中走势,收盘价格可能会有所变化。投资者可能需要密切关注Apellis Pharmaceuticals未来的业务发展和财务状况,以评估公司的长期投资价值。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 瑞穗下调目标价,Apellis Pharmaceuticals盘中大跌5.03%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["APLS"],"gpt_icon":0},{"id":"2535300603","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘大幅下挫5.03%报16.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535300603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535300603?lang=zh_cn&edition=full","pubTime":"2025-05-15 02:12","pubTimestamp":1747246372,"startTime":"0","endTime":"0","summary":"北京时间2025年05月15日02时12分,Apellis Pharmaceuticals, Inc.股票出现波动,股价急速下挫5.03%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为1.19%。Apellis Pharmaceuticals, Inc.公司简介:Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物, 通过抑制补体系统来治疗具有高度未满足需求的疾病,在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505150212539759b898&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505150212539759b898&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","LU1093756168.USD","BK4139","BK4588","BK4585","APLS","LU1093756325.SGD"],"gpt_icon":0},{"id":"2535079611","title":"瑞穗银行:维持Apellis Pharmaceuticals(APLS.US)评级,由中性调整至中性评级, 目标价由30.00美元调整至20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535079611","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535079611?lang=zh_cn&edition=full","pubTime":"2025-05-14 22:54","pubTimestamp":1747234450,"startTime":"0","endTime":"0","summary":"瑞穗银行:维持Apellis Pharmaceuticals(APLS.US)评级,由中性调整至中性评级, 目标价由30.00美元调整至20.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/14225450394651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["161121","APLS"],"gpt_icon":0},{"id":"2534487899","title":"B of A Securities:下调Apellis Pharmaceuticals(APLS.US)评级,由买入调整至中性评级, 目标价由41.00美元调整至23.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534487899","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534487899?lang=zh_cn&edition=full","pubTime":"2025-05-09 21:23","pubTimestamp":1746797017,"startTime":"0","endTime":"0","summary":"B of A Securities:下调Apellis Pharmaceuticals(APLS.US)评级,由买入调整至中性评级, 目标价由41.00美元调整至23.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/09212350279348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["APLS"],"gpt_icon":0},{"id":"2534154546","title":"加拿大皇家银行:维持Apellis Pharmaceuticals(APLS.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由21.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534154546","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534154546?lang=zh_cn&edition=full","pubTime":"2025-05-09 01:01","pubTimestamp":1746723694,"startTime":"0","endTime":"0","summary":"加拿大皇家银行:维持Apellis Pharmaceuticals(APLS.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由21.00美元调整至18.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/09010150242521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["APLS"],"gpt_icon":0},{"id":"2533134574","title":"Scotiabank:维持Apellis Pharmaceuticals(APLS.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由28.00美元调整至20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533134574","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533134574?lang=zh_cn&edition=full","pubTime":"2025-05-08 22:24","pubTimestamp":1746714296,"startTime":"0","endTime":"0","summary":"Scotiabank:维持Apellis Pharmaceuticals(APLS.US)评级,由与大盘持平调整至与大盘持平评级, 目标价由28.00美元调整至20.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/08222450241693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["APLS"],"gpt_icon":0},{"id":"2533334111","title":"富国银行:维持Apellis Pharmaceuticals(APLS.US)评级,由持股观望调整至持股观望评级, 目标价由30.00美元调整至26.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533334111","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533334111?lang=zh_cn&edition=full","pubTime":"2025-05-08 21:24","pubTimestamp":1746710663,"startTime":"0","endTime":"0","summary":"富国银行:维持Apellis Pharmaceuticals(APLS.US)评级,由持股观望调整至持股观望评级, 目标价由30.00美元调整至26.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/08212450241031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["APLS"],"gpt_icon":0},{"id":"2533133566","title":"Baird:维持Apellis Pharmaceuticals评级,由优于大市调整至优于大市评级, 目标价由55.00美元调整至47.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533133566","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533133566?lang=zh_cn&edition=full","pubTime":"2025-05-08 20:46","pubTimestamp":1746708362,"startTime":"0","endTime":"0","summary":"Baird:维持Apellis Pharmaceuticals(APLS.US)评级,由优于大市调整至优于大市评级, 目标价由55.00美元调整至47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050820514794f08522&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050820514794f08522&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APLS"],"gpt_icon":0},{"id":"2533052935","title":"Apellis Pharmaceuticals, Inc.盘中异动 快速下跌10.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533052935","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533052935?lang=zh_cn&edition=full","pubTime":"2025-05-07 21:30","pubTimestamp":1746624624,"startTime":"0","endTime":"0","summary":"北京时间2025年05月07日21时30分,Apellis Pharmaceuticals, Inc.股票出现波动,股价快速跳水10.25%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。Apellis Pharmaceuticals, Inc.公司简介:Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物, 通过抑制补体系统来治疗具有高度未满足需求的疾病,在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507213024975203b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507213024975203b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PULM","BK4139","BK4007","LU1093756168.USD","BK4585","APLS","LU1093756325.SGD","BK4505","BK4588"],"gpt_icon":0},{"id":"2532086062","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532086062","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532086062?lang=zh_cn&edition=full","pubTime":"2025-05-01 02:46","pubTimestamp":1746038776,"startTime":"0","endTime":"0","summary":"北京时间2025年05月01日02时46分,Apellis Pharmaceuticals, Inc.股票出现波动,股价快速上涨5.00%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.14%。Apellis Pharmaceuticals, Inc.公司简介:Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物, 通过抑制补体系统来治疗具有高度未满足需求的疾病,在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501024616a6cf2ca5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501024616a6cf2ca5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","BK4585","BK4588","LU1093756168.USD","APLS","LU1093756325.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":-0.0721},{"period":"3month","weight":-0.0877},{"period":"6month","weight":-0.4579},{"period":"1year","weight":-0.5166},{"period":"ytd","weight":-0.4394}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.0354},{"period":"3month","weight":0.1307},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.1172},{"period":"ytd","weight":0.0585}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apellis Pharmaceuticals, Inc.于2009年9月25日根据德拉华州法律成立。该公司是一家商业阶段的生物制药公司,专注于发现、开发和商业化新型治疗化合物,通过在补体级联中的中心蛋白C3水平上抑制补体系统(作为免疫系统的一个组成部分)来治疗具有高度未满足需求的疾病。2023年2月,美国食品药品监督管理局(FDA)批准了SYFOVRE,这是首个获批治疗继发于年龄相关性黄斑变性(GA)的地理萎缩的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.0274},{"month":2,"riseRate":0.625,"avgChangeRate":0.032574},{"month":3,"riseRate":0.5,"avgChangeRate":0.022263},{"month":4,"riseRate":0.625,"avgChangeRate":0.039768},{"month":5,"riseRate":0.375,"avgChangeRate":-0.036849},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.082893},{"month":8,"riseRate":0.857143,"avgChangeRate":0.144378},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.143331},{"month":10,"riseRate":0.428571,"avgChangeRate":0.015269},{"month":11,"riseRate":0.714286,"avgChangeRate":0.147845},{"month":12,"riseRate":0.75,"avgChangeRate":0.124183}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}